Allt inom Issuance

Today Nanexa AB (publ) (”Nanexa” or the “Company”) announces the outcome of the Company’s rights issue of approximately SEK 121m (the “Rights Issue”), for which the subscription period ended on 26 October 2023. The outcome of the Rights Issue shows that 42,146,268 shares, corresponding to approximately 34.7 percent of the Rights Issue, have been subscribed with and without the support of subscription rights. Hence, guarantee commitments of 32,853,732 shares, corresponding to approximately 27.1 percent of the offered shares, will be utilised. The Rights Issue will provide the Company with SEK 75m before deduction of transaction costs.

Nanexa AB (publ) (”Nanexa” or the ”Company”) carries out an issue of shares of approximately SEK 121 million before transaction costs with preferential rights for the Company’s existing shareholders (the “Rights Issue”). The board of directors resolved today, on September 21, 2023, on the Rights Issue on the basis of the authorisation from the annual general meeting on June 9, 2023. The Company has received subscription undertakings and guarantee commitments in a total amount of SEK 75 million, which corresponds to approximately 62 per cent of the Rights Issue. The purpose of the Rights Issue is to strengthen the Company’s financial position, to enable the planned clinical studies as well as carry out other value creating activities supporting PharmaShell and the NEX projects. As a consequence of the Rights Issue, the board of directors has resolved to delay the publication of the Company’s interim report for the period January – September 2023 until November 30, 2023.